Current Funding Opportunities for Scientists

Lists of funding opportunities are updated weekly. New funding opportunities for scientists are distributed in the VPRI Update newsletter.

To submit funding opportunities, and/or be added to the VPRI Update mailing list, please send your request to VPRI@smh.ca.

Opportunities are categorized by Sponsor Type (Tri-Agency, Other Canadian, International & NIH). Filter opportunities by keyword (e.g. Sponsor Type, CIHR, user-supplied keyword, etc.) using the Search box at right.

Sponsor TypeFunding Program TitleAmount and DurationDescriptionDeadline
Tri-AgencyPre-Announcement: Transforming Public Health: 2021- Chief Public Health Officer of Canada report funding opportunityUp to $100,000 per year for 1 year.The CIHR Institute of Population and Public Health (IPPH) and CIHR Centre for Research on Pandemic Preparedness and Health Emergencies have partnered to launch a funding opportunity in January 2022 that will support research on the population and public health priorities identified in the 2021 CPHO Annual Report. A list of research priorities aligned with the 2021 CPHO Annual Report are planned to be published in a supplementary document to the CPHO report website in January.Scheduled to be launched in January 2022, with complete details about project requirements, adjudication, the application process and deadlines available then.
Tri-AgencyCIHR-Canadian Psychiatric Association (CPA) Glenda M. MacQueen Memorial Career Development Award for Women in Psychiatry$100,000 for 1 year.This supports the early-stage development of women who will lead the future of academic psychiatry. The applicant must:
- Be an early career independent researcher (term to qualify for ECR status has been extended to 0-84 months (or seven years),
- Self-identify as a woman and/or demonstrate a track record of supporting the career development of women in academic psychiatry,
- Be a psychiatrist who is licensed to practise in a Canadian province and who is certified in psychiatry by the Royal College of Physicians and Surgeons of Canada or by a provincial college,
- Be an Active or early career psychiatrist member in good standing of the CPA at the time of application.
February 1, 2022.
Tri-AgencySSHRC Insight Development Grants: February 2022 Competition$7,000 to $75,000 for 1-2 years.Insight Development Grants support research in its initial stages. They enable the development of new research questions as well as experimentation with new methods, theoretical approaches and/or ideas. Funding is provided for short-term research development projects, of up to two years, proposed by individuals or teams.February 2, 2022.
Tri-AgencyCIHR Spring 2022 Reviewer in Training (RiT) Program: Call for Expressions of Interest--This offers Early Career Researchers (ECRs) a learning opportunity to gain a better understanding of the elements of high quality review and the peer review process through direct participation in the Project Grant competition with the support of a Mentor. RiT participants will be assigned up to three applications to conduct practice reviews, attend the peer review meeting, present one review, and participate in the committee meeting.
Note: Fall 2021 applicants do not need to re-apply. All eligible applications to the Fall 2021 RiT program will automatically be considered for the Spring 2022 RiT program.
Applications require an institutional letter that confirms ECR status. If you plan to apply, please let us know via email to VPRI@smh.ca to arrange for this letter.
February 4, 2022.
Tri-AgencyCIHR Other: Network Grants in Oral Health and Bone HealthOral Health: Up to $400,000 per year for up to 5 years; Bone Health: Up to $400,000 per year for up to 3 years.This will provide support for the creation of two networks: one in the priority area of Oral Health and one in the priority area of Bone Health. The aim of these networks will be to provide research leadership, foster innovative research and practices, build capacity and provide a forum that engages the research community and its partners (including but not limited to industry, charities, and patients and their careers). The networks are expected to serve as a resource for collaborating, capacity building, and knowledge mobilization.Registration: February 8, 2022.
Application: March 8, 2022.
Tri-AgencyCIHR Project Grant: Spring 2022Project Grant funding levels are proportionate to the requirements of the research proposed, which is expected to vary by research field, research approach, and scope of proposal activities. The Project Grant program is designed to capture ideas with the greatest potential for important advances in fundamental or applied health-related knowledge, health care, health systems, and/or health outcomes by supporting projects of research proposed and conducted by individual researchers or groups of researchers in all areas of health. The best ideas may stem from new, incremental, innovative, and/or high-risk lines of inquiry or knowledge translation approaches.Registration: February 9, 2022.
Application: March 9, 2022.
Tri-AgencySSHRC Partnership Grants Stage 1Up to $20,000. Stage 2: Up to $500,000 per year over 4-7 years, up to a total of $2,500,000.Partnership Grants are intended for large teams working in formal collaboration between postsecondary institutions and/or organizations from the public, private and/or not-for-profit sectors. Funds are available to support a variety of formal partnership initiatives, e.g. disciplinary, interdisciplinary, inter-institutional, international and/or cross-sectoral, in any of the disciplines and themes eligible for funding at SSHRC.Stage 1: February 10, 2022.
Stage 2 (by invitation only): TBD.
Tri-AgencyNSERC Collaborative Research and Training Experience (CREATE): Expression of InterestUp to $150,000 in the first year and up to $300,000 per each additional year to a maximum of $1.65M over 6 years.U of T is holding an internal competition to select applicants to the 2022 NSERC CREATE Program. Only those teams invited by U of T can submit a full application. CREATE supports the training of teams of outstanding students and postdoctoral fellows from Canada and abroad in the natural sciences and engineering, through the development of innovative training programs that encourage collaborative and integrative approaches, address significant scientific challenges associated to Canada's research priorities, and facilitate the transition of new researchers from trainees to productive employees in the Canadian workforce. For more information and questions, please contact Jessica Keating.U of T Expression of Interest: March 1, 2022. U of T Letter of Intent: March 12, 2022. Sponsor Deadline: May 1, 2022.
Tri-AgencyCIHR Operating Grant: Healthy Cities Research Initiative (HCRI): Data Analysis Using Existing Databases and CohortsUp to $100,000 for 1 yearThis funding opportunity will support research using existing data that is focused on improving the health, wellness and health equity of urban populations, relevant to the following research areas:
- Healthy Cities Intervention Research General Pool: This will fund projects that use existing cohort data, administrative datasets, surveys, registries, and data platforms and that are relevant to HCRI's goal and objectives.
- Healthy Cities Intervention Research Urban Indigenous Health Pool: This will fund projects that in addition to aligning with the requirements of the general pool also focus on Urban Indigenous Health Research.
April 12, 2022.
Tri-AgencyCIHR Catalyst Grant : HIV/AIDS and STBBI Community-Based ResearchUp to $100,000 per year for 1 year.The aim is to provide seed money to support HIV and/or other STBBI community-based research (CBR) research activities which represent a first step towards the pursuit of more comprehensive funding opportunities (e.g., operating grants).April 24, 2022.
Tri-AgencyCIHR Operating Grant: HIV/AIDS and STBBI Community-Based ResearchUp to $150,000 per year for 3 years.The aim of is to contribute to the creation, dissemination and use of health-related knowledge, and to help develop research capacity, by supporting original, high-quality projects proposed and conducted in partnership between the community and academia.April 24, 2022.
Tri-AgencyCIHR Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)Research Grant: Up to $2,000,000 per year for up to 6 years; Collaborating Centre: Up to $350,000 per year for up to 6 years.This funding opportunity will support projects relevant to the following research areas:
An I-HeLTI Intervention Cohort Research Study that will encompass the continuum of care and prevention of non-communicable diseases, from preconception to pregnancy, infancy and early childhood with a life trajectory perspective. An I-HeLTI Collaborating Centre that will steward the emerging I-HeLTI cohort, governance processes and data management. Eligibility to apply to this funding opportunity is limited to the three CIHR-funded I-HeLTI research teams.
June 6, 2022.
Tri-AgencySSHRC Partnership Engage GrantsBetween $7,000 and $25,000.These grants provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector.March 15, 2022; June 15, 2022; September 15, 2022 and December 15, 2022.
Tri-AgencyNSERC Alliance/Mitacs Accelerate Grants--This is for applicants seeking support from both an Alliance grant and Mitacs Accelerate, to apply through a single application submission and review process. Applicants who wish to include Mitacs Accelerate internships in their Alliance application should contact their local Mitacs business development representative to obtain the NSERC/Mitacs joint application form.Ongoing
Tri-AgencyNSERC Alliance Grants$20,000 to $1 million per year for 1-5 yearsSupport university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Tri-AgencyNSERC Alliance International- Catalyst Grants: These will allow Canadian researchers to identify and initiate the first stage of collaboration. Value: $25,000 for 1 year.
- Collaboration Grants: These will allow Canadian researchers to participate in internation
These are for Canadian university researchers working in the natural sciences and engineering in partnership with international collaborators from the academic sector. The overall objectives are to: 1) allow Canadian researchers to initiate the development of international collaborations; and 2) provide support for Canadian researchers participating in international collaborative projects of global importance and benefit to Canada. The applicant and any Canadian co-applicants must have an active NSERC peer-reviewed grant, as primary applicant, at the time of application.
NOTE: All NSERC grant applications must be submitted through the University of Toronto Research Services Office.
No Deadline
Other CanadianCanadian Partnership for Women and Children's Health (CanWaCH): Canadian Collaborative for Global HealthMaximum $125,000 for up to 1 year. This will bring together Canadian and global partners to generate solutions to urgent data challenges in global health and rights, and gender equality where (a) Canada has made significant contributions to date; and (b) significant gaps in data capacity, knowledge, or resources remain. Selected Labs will investigate the underlying barriers to effective data progress in areas of global health, human rights, and gender equality, and work together to co-create potential solutions. There must be at least one Canadian research organization and one Canadian civil society organization (CSO) as part of the team for Canadian based projects. For projects based internationally, a partner(s) registered in those countries is required.January 31, 2022.
Other CanadianPre-Announcement: New Frontiers in Research Fund (NFRF) Special Call: Research for Post-Pandemic RecoveryUp to $500,000 total for 2 years.This will support support a diverse portfolio of projects that directly address one or more of the research priorities outlined in the UN Research Roadmap for COVID-19 Recovery. Projects are expected to be interdisciplinary, and all project teams must have an expert in social/economic/socio-economic research and implementation science among the team of principle investigators, to reflect the socio-economic recovery framework of the Roadmap. All projects are also expected to have an international dimension, and inclusion of team members from lower-middle- or lower-income countries is strongly encouraged. Scheduled to be launched in February 2022, with complete details about project requirements, adjudication, the application process and deadlines available then.
Other CanadianCollege of Family Physicians of Canada (CFPC) Research Grants: Various OpportunitiesDaniel Glazier Research Grant in Adolescent Mental Health and Substance Abuse:Up to $5,000 for up to 2 years.
Janus Research Grants and the D.M. Robb Community-Based Research Grant: Intermediate-level or experienced researchers: Up to $15,000 for up to 2 years; Novice or intermediate-level researchers: Up to $7,500 for up to 2 years.
Scholarly Work in Family Medicine Education Grant: $10,000 for up to 2 years.
For all grants, the applicant must be a member of the CFPC who has been in good standing for at least one year.
Daniel Glazier Research Grant in Adolescent Mental Health and Substance Abuse: This grant is meant to support research that will help family physicians in assessing and treating mental health and substance abuse among adolescents and young adults up to the age of 25.
Janus Research Grants and the D.M. Robb Community-Based Research Grant: These support academic and community-based family physician CFPC in carrying out research projects that meet the changing needs of their patients and communities in Canada. The D.M. Robb Grant supports community-based family practice research projects.
Scholarly Work in Family Medicine Education Grant: This grant funds scholarly work with the intent of advancing family medicine education broadly. Projects that support CFPC educational initiatives will receive special consideration.
February 1, 2022.
Other CanadianCollege of Family Physicians of Canada (CFPC) Continuing Professional Development (CPD) Grants: Various OpportunitiesDaniel Glazier CPD Grant in Adolescent Mental Health and Substance Abuse: $5,000.
Hollister King Rural Family Practice CPD Grant: $5,000.
Janus CPD Grants: $5,000.
Family Medicine Global Health Project Grant: $3,000.
For all grants, the applicant must be a member of the CFPC who has been in good standing for at least one year and must be in active practice.
Daniel Glazier CPD Grant in Adolescent Mental Health and Substance Abuse: This grant supports CPD or the creation of clinical programs or tools to help family physicians in assessing and treating mental health and substance abuse among adolescents and young adults up to the age of 25.
Hollister King Rural Family Practice CPD Grant: Supports academic and community-based family physician CFPC members who are actively practising in a rural setting and wish to carry out CPD activities related to meeting the changing needs of their patients and communities within Canada. .
Janus CPD Grants: Support academic and community-based family physician CFPC members who are in active practice and wish to carry out CPD activities related to meeting the changing needs of their patients and communities within Canada.
Family Medicine Global Health Project Grant: Support for CFPC members in engaging in global health care projects either in Canada or abroad and in promoting family medicine abroad. Clinical activities, teaching, research, or conference attendance will be considered.
February 1, 2022.
Other CanadianCollege of Family Physicians of Canada (CFPC) Project Development Support Programs: Various OpportunitiesRacialized Communities Leadership Grant in Family Medicine: $10,000.
Marco Terwiel Rural Family Medicine Innovation Grant: $5,000.
For all grants, the applicant must be a member of the CFPC who has been in good standing for at least one year.
Racialized Communities Leadership Grant in Family Medicine: This supports each recipient's focus and leadership and support their project or initiative that will directly benefit one or more racialized communities. The project must enhance the delivery of primary care to one or more racialized communities in Canada. Applicants must self-identify as Indigenous, Black, or a member of another racialized community.
Marco Terwiel Rural Family Medicine Innovation Grant: This grant is for a family physician looking to develop or enhance a tool, resource, or app, for example, to address the complexity of patients access to care in rural and remote areas. Applicants must be working working in a northern, rural, or remote community.
February 1, 2022.
Other CanadianDigital Research Alliance of Canada: Data Champions Pilot Project CallUp to $50,000 per applicant for 1 year.This funding call aims to build national research capacity and deliver on the Alliance mandate to create a broad and integrated Canadian digital research infrastructure (DRI) ecosystem. The call will address the needs of the research community related to Research Data Management (RDM), while promoting an equitable and inclusive DRI environment in Canada. The role of the Data Champion is to develop activities at the local, regional and/or national level that advance awareness, understanding, development, and adoption of RDM tools, best practices, and resources in Canada.February 3, 2022.
Other CanadianOntario Institute for Cancer Research (OICR) Window-of-Opportunity (WOO) Network: 2022 Portfolio Trials Call for ConceptsUp to $450,000 for up to 2 years.This provides funding support for pre-surgical immune-modulatory WOO trials in treatment-naïve or early disease patients. The Network provides prioritized WOO studies with trial development support, funding, translational analysis, and knowledge dissemination. The WOO Network also builds study capacity through mentoring of new investigators, industry partnerships, patient engagement, data analysis and sharing network expertise.Concept Proposal: February 7, 2022.
Full Application (by invitation): May 16, 2022.
Other CanadianGenome Canada Genomic Applications Partnership Program (GAPP) Total project size $300,000 to $6 million for 2-3 years.This funds downstream research and development (R&D) projects that address real-world opportunities and challenges defined by "Receptor" organizations such as industry, government, or not-for-profit entities. These projects are co-funded by Receptors and other stakeholders and must have the potential to generate significant social and/or economic benefits for Canada. Please contact Ann Meyer, Advisor, Sector Innovation & Programs (ameyer@OntarioGenomics.ca) with any questions and/or to initiate your application process.February 8, 2022.
Other CanadianAMS Healthcare: Funding in Compassion and Artifical Intelligence (AI) $20,000 for 12 months. These support projects that will generate new knowledge and evidence to advance the education/training of undergraduate, graduate, and practicing healthcare professionals, and clinical health systems, and related field researchers on compassionate care and AI. February 22, 2022.
Other CanadianMitacs Internships - Current Promotions_Connect your students to research and innovation opportunities with small and medium enterprises (SMEs): For a limited time, Mitacs is increasing its funding for SMEs and not-for-profits (NFP). Qualifying partners pay only 25% of the cost of an innovation project done in collaboration with a Canadian post-secondary institution.
Expanded Eligibility: Current students and recent grads (within two years of graduation) are now eligible. For a limited time, your SME or NFP partner pays only 25% of the first full year of an innovation project. NOTE: Partners in these fields are in particular need of research intern engagement: Municipalities of all sizes to advance policy and innovation, Canadian hospitals.
If you have any questions or need assistance, please contact the Mitacs business development representative for Unity Health, Rihanna Malcolm.

March 1, 2022.
Other CanadianU of T 2021-23 Joint EMHSeed And XSeed Call For Proposals $60,000 per year for two years. The $60,000 per year amount for each project is the sum of total cash invested by each of the participating Faculty and departments/institutes.This is an interdivisional research funding program designed to promote multi-disciplinary research and catalyze new innovative partnerships between a co-PI from the Faculty of Applied Science and Engineering (FASE) and a co-PI from outside Engineering. EMHSeed funding is for faculty members that have an appointment in the Faculty of Medicine and XSeed is for faculty members with an appointment at DLSPH and other divisions.
If you are interested in applying, please contact VPRI@smh.ca, as matching funding is required.
March 7, 2022.
Other Canadian14th JPIAMR Transnational Call: Disrupting Drug Resistance Using Innovative DesignUp to $150,000 per year for 3 years.This call will support research into therapeutic/agricultural interventions based on the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents to treat bacterial or fungal infections in One Health settings. For more information, please consult the JPIAMR website.Pre-Proposal: March 8, 2022.
Full Proposal (by invitation): July 5, 2022.
Other CanadianKidney Foundation of Canada (KFOC): Allied Health Kidney Research Grants$50,000 per year for 1 or 2 years.The purpose is to encourage allied health professionals to pursue research relevant to the areas of nephrology and organ donation, including clinical, health services, social, cultural, environmental and population health research. To be eligible for this grant the principal applicant must be an allied health professional.March 15, 2022.
Other CanadianOntario Research Fund - Research Excellence (ORF-RE) Round 11Stream 1: $500,000 to $2,000,000 for up to 5 years.
Stream 2: $300,000 to $1,000,000 for up to 4 years.
This provides research institutions with funding to support the operational costs of major projects of strategic value to the province. The fund provides up to one third of the total value of a project, with the remaining two thirds coming from a combination of private sector and institutional contributions. Round 11 has two application streams:
- Stream 1: General - Basic and Applied Research: Open to all research disciplines.
- Stream 2: Targeted - Experimental Research: Funds projects that demonstrate strong commercialization potential, where the innovation is at a Technology Readiness Level (TRL) of 3 or higher. Targeted projects are in the following sectors: information communications technologies; life sciences and medical devices; industrial technologies. Requires collaboration with an Ontario-based company.
If you are planning to apply to this opportunity, please let us know by email to VPRI@smh.ca.
Sponsor Deadline: March 21, 2022.
Other CanadianU of T-Hebrew University of Jerusalem (HUJI) Research & Training Alliance: Call for Joint ProposalsUp to $150,000 per year for up to 4 years to support U of T and HUJI researchers/trainees, one postdoctoral fellow.This calls for joint proposals for a Research & Training Alliance to develop a collaborative research focus and the exchange of graduate and undergraduate students and researchers, as well as one post-doctoral fellow. Proposals are invited from the Life Sciences, Natural Sciences and Applied Sciences. Projects must include research team participants of three or more PIs from both U of T and HUJI. U of T applicants must have a faculty appointment with U of T and be eligible to hold research funding.
If you have questions, please contact the University of Toronto Office of the Vice President International or Hebrew University International Office.
March 21, 2022.
Other CanadianGlobal Alliance for Chronic Diseases (GACD) 7th Call for Applications For CIHR, up to CAD $400,000 per year for up to 5 years.This focuses on implementation research to reduce the non-communicable disease burden by targeting critical life stages and key transitions between life stages. Research should aim to improve health equity in low- and middle-income countries or among disadvantaged populations in high-income countries. While not yet available, applicants will be directed to view the call text on CIHR's ResearchNet website for complete information regarding CIHR-specific research areas of interest.May 31, 2022.
Other CanadianJ. P. Bickell Foundation Medical Research Grant Range from $25,000 - $80,000.For medical research, with a focus on innovative basic/translational research projects led by early career researchers. Please note that Unity Health can submit only one application for this grant. To be considered, send a summary of your proposed project/program (maximum 1 page) to VPRI@smh.ca by April 7, 2022.April 30, 2022.
Other CanadianMitacs Accelerate: Eligibility and New Program Updates--Options and enhancements include expanding eligibility for both interns and external sponsoring partners, and increasing support levels for some partners.

Mitacs Accelerate-Expanded Eligibility Criteria: Mitacs can now support undergraduate students as interns on a Mitacs Accelerate grant. In addition, municipalities and hospitals are now considered to be eligible partner organizations for Mitacs Accelerate

Mitacs SME Discount Model:Until February 1, 2022, a partner organization that is a small/medium-sized enterprise (SME) in the for-profit or non-profit sector will only be charged 25% of the overall project costs instead of Mitacs's typical 50% cost-sharing ratio. Details here: Link.

Accelerate Industrial Post-Doctoral Fellowship-New Funding Model: This funding stream provides $60,000/year for a post-doctoral fellow, where the partner organization must contribute $30,000 plus applicable taxes per year. Details here: Link.

Mitacs and National Research Council (NRC) collaborative funding stream for R&D projects: Support for 250 graduate and post-graduate student internships within the NRC's Challenge and Supercluster support programs. Details here: Link.
--
Other CanadianNew Mitacs Initiatives and Opportunities--Mitacs Parterships with Municipalities: Professors, postdoctoral fellows, graduate students, college students and undergraduate students can now put their talent to work on a collaborative research project at a municipality that needs your expertise. Canadian municipalities of all sizes are now eligible partners for co-funded projects involving post-secondary researchers through Mitacs programs. Details here: Link.

Mitacs Partnerships with Hospitals: This initiative empowers Canadian hospitals no matter the size, by providing access to the brightest post-secondary researchers and funding for innovative projects. Whether you are a hospital administrator looking to collaborate with experts across a myriad of disciplines or an academic whose research could benefit a hospital, Mitacs can help. Details here: Link.

Indigenous Pathways Initiative: Projects are a minimum of four months in duration - they can be longer - and now Indigenous-owned businesses and organizations’ contribution is only 25% of the cost of projects that have an Indigenous partner organization and/or an intern who is Indigenous. Details here: Link.
--
Other CanadianUniversity of Toronto Institutional Strategic Initiatives (ISI)From $50,000-$300,000 per year for up to 3 years.ISI awards are intended to establish research capacity in high-priority areas, with the goal of realizing transformational impacts on issues of societal importance. Proposed investigator-initiated initiatives must meet the following key criteria: 1) Address a significant challenge and associated research questions that requires an interdisciplinary approach; 2) Matching funds secured from three or more Academic Divisions; 3) Path to sustainability demonstrated by a clear opportunity for external funding. Ongoing
Other CanadianCollaboration Opportunities: National Research Council Canada (NRC) Challenge Programs--The NRC offers potential opportunities for collaboration in the following areas:

- Aging in Place
- Artificial Intelligence for Design
- Disruptive Technology Solutions for Cell and Gene Therapy
- High-throughput and Secure Networks
- Pandemic Response

Potential collaborators can register their interest to work with NRC on the Challenge Programs website.
Ongoing
Other Canadian Government of Canada: CanExport for Innovators Maximum of $75,000 Specifically designed to promote and enhance Canada's international innovation efforts. Eligible expenses may include international and local travel, accommodation, meals, meeting costs, legal fees to support formalized partnerships, and other costs related to international collaboration.

Applications must be submitted at least 8 WEEKS prior to the anticipated start date of the activities.
Continuous
Other CanadianWeston Brain Institute: Early Phase Clinical Trials: CanadaUp to $1,500,000 per project for up to 4 yearsFunding for clinical trials and/or clinical trial sub-studies with excellent preliminary data.Rolling deadline
Other CanadianPhysicians' Services Incorporated (PSI) Foundation: Health Research Grant & New Investigator GrantHealth Research Grant: Up to $250,000 for 3 years.

New Investigator Grant: Up to $300,000 for 3 years.
Areas of Support: clinical research, medical education research, health systems research. Applicant must be a College of Physicians and Surgeons of Ontario licensed MD. New Investigators must be within five years of their first academic appointment. Rolling deadline
Other CanadianTelus FundsVariousFor entertaining and engaging web series with the potential to positively impact families and friends providing care for loved ones struggling with a health condition.Various
Other CanadianOntario Centre of Innovation (OCI) Voucher for Innovation and Productivity (VIP) Program Minimum of $20,000 up to a maximum of $150,000 per year towards the direct costs of research (Industry Partner contribution has to be minimum of 1:1 cash match to the OCE contribution, where at least 50% must be spent at the post-secondary institution.)This program helps companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario's industry and publicly funded post-secondary institutions and research hospitals. VIP projects are intended to generate economic benefit for companies in Ontario (including job creation/retention, new revenue generation, investment attraction, cost savings, value chain development), in the short-to-medium term (e.g. within three years of project completion).

If you are interested, please contact Samar Saneinejad (Samar.Saneinejad@unityhealth.to ).
No Deadline
InternationalEmbassy of the United States of America - Canada (U.S. Mission in Canada) Public Affairs Section (PAS): Combatting COVID-19 Grant ProgramBetween USD $15,000-$100,000 for up to 24 months.
This invites proposals that that strengthen the bilateral ties between the U.S. and Canada and support the Roadmap for a Renewed U.S.-Canada Partnership Pillar Combatting COVID-19, including, but not
limited to:
- Programs and initiatives to combatting mis- and dis-information around COVID-19 and vaccinations and promote the importance of science-based public health measures in response to the pandemic.
- Messaging, information, and educational programs and campaigns that engage youth and underserved communities, and that address information and other disparities between communities and rural and urban audiences.
January 14, 2022; March 7, 2022; May 4, 2022; July 6, 2022.
InternationalAmerican Institute for Cancer Research (AICR) Investigator-Initiated Research Grant ProgramUp to USD $75,000 direct costs per year for up to 3 years.This welcomes proposals for research addressing the effects of diet, nutrition, body composition or physical activity on cancer risk and outcomes.Letter of Intent: January 21, 2022.
Full Application (by invitation): March 11, 2022.
InternationalPfizer Global Medical Grants (GMG) Request for Proposals (RFP): Optimizing Telehealth Use in CanadaUp to $30,000 for 1 year.This supports quality improvement initiatives that enhance the virtual quality of care in areas outlined below or access to care with telemedicine.
- Informational continuity - how can we ensure that information on prior events is properly used to provide care that is appropriate to the patient's current circumstance?
- Relational continuity - how can we elevate and bridge the ongoing relationship between patients and providers which is the undergirding that connects care over time and bridges discontinuous events?
- Management continuity - how can we ensure that care received from different providers is connected in a coherent and efficient way to provide optimal patient care?
January 25, 2022.
InternationalAmerican Association for Cancer Research (AACR) Gertrude B. Elion Cancer Research AwardUSD $75,000 for one year.This represents an effort to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on research in cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature. At the start of the grant term on July 1, 2022, applicants must hold a tenure-eligible appointment (or equivalent, if institution does not follow a tenure system) at the rank of assistant professor and have completed their most recent doctoral degree within the past 11 years. Applicants with a medical degree must have completed their most recent doctoral degree or medical residency (or equivalent) - whichever date is later - within the past 11 years.January 31, 2022.
InternationalAcademy of Nutrition and Dietetics Foundation: Various OpportunitiesAnn A. Hertzler Memorial Research Grant: USD $15,000.
Diabetes (DDPG) DPG Karen Goldstein Memorial Grant for Diabetes MNT Application: USD $20,000.
Julie O'Sullivan Maillet Research Grant: USD $1,000.
Molly Kellogg Grant for Advancement in Nutrition Counseling:USD $3,000.
Ann A. Hertzler Memorial Research Grant: Proposals should evaluate the effectiveness of medical nutrition therapy (provided by RDNs) in adult patients that are overweight with low socioeconomic status.
Diabetes (DDPG) DPG Karen Goldstein Memorial Grant for Diabetes MNT Application:Provides financial support to a Diabetes DPG member for outcomes research in diabetes medical nutrition therapy.
Julie O’Sullivan Maillet Research Grant: For a research project that aims to demonstrate the value of dietetics professionals on the health of the public or demonstrate the evolving role of dietetics professionals in the profession.
Molly Kellogg Grant for Advancement in Nutrition Counseling: This is to advance counseling skills excellence in the dietetic profession by providing financial support to RDs and DTRs to pursue research in the nutrition counseling process.
February 1, 2022.
InternationalUS Centers for Disease Control and Prevention: Enhancing Capacity for Strategic and Applied Research Activities in Support of Control and Elimination of Malaria and Other Parasitic DiseasesUp to USD $2,400,000.This seeks to fund critical research and evaluation activities with the potential to yield high impact public health findings and to improve strategies that will decrease the overall burden of parasitic diseases and increase the health and well-being of affected populations. Research topics include identifying and tracking morbidity, developing and testing better diagnostic tools, improving surveillance, and developing and evaluating interventions that can reduce or interrupt transmission of parasitic diseases including reduction of their vectors.Letter of Intent (optional): February 1, 2022.
Application: March 1, 2022.
InternationalNational League for Nursing (NLN) Nursing Education Research Grants ProgramUp to USD $30,000 for 1 or 2 years.This supports high-quality studies that contribute to the development of the science of nursing education. The NLN-funded grants promote diversity of research topics and support investigators who demonstrate rigor and innovative approaches to advance the field of nursing education research. Principal investigators must be current NLN members.February 3, 2022.
InternationalAlzheimer's Drug Discovery Foundation (ADDF): Core Funding ProgramsDrug Development: Up to USD $600,000 for 1 year.
Program to Accelerate Clinical Trials (PACT):Up to USD $3,000,000 for multi-year projects.
Neuroimaging and CSF Biomarker: Up to USD $600,000 for 1 year.
Prevention Pipeline: Up to USD $3,000,000 for multi-year projects.
NOTE: Anti-amyloid approaches and cholinesterase inhibitor proposals will not be considered for the Drug Development or PACT RFPs.
Drug Development: This supports in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

Program to Accelerate Clinical Trials (PACT): This supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
Neuroimaging and CSF Biomarker: This aims to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
Prevention Pipeline: This supports studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
NOTE: Anti-amyloid approaches and cholinesterase inhibitor proposals will not be considered for the Drug Development or PACT RFPs.
Letter of Intent: February 4, 2022; May 20, 2022; September 30, 2022.
Invited Full Proposal: April 8, 2022; July 22, 2022; December 2, 2022.
InternationalNorth American Spine Society (NASS): Various OpportunitiesUSD $20,000-$40,000 per year.NASS supports basic, clinical and translational science. The goal is to improve quality spine care for patients and understanding of underlying disorders. The Principal Investigator is required to be a NASS member.
- Research Grants: Provide funding for promising research projects by qualified investigators in the field of spine.
- Young Investigator Grants: Principal investigators may be any age. MD applicants must be within five years of completion of training at the time of application; PhD applicants must be within five years of their post-doc training.
- Nontraditional Nonsurgical Treatment Grant: Supports research of disc-related and/or neuropathic back pain by nonsurgical techniques. These funds must be used for new, nontraditional methods of nonsurgical treatment of such back and neck pain and radiculopathy.
Letter of Proposal: February 7, 2022.
Full Proposal (by invitation): May 9, 2022.
International Patient-Centered Outcomes Research Institute (PCORI): Improving Methods for Conducting Patient-Centered Outcomes Research (PCOR)Up to USD $750,000 per year for up to 3 years.PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by PCOR/clinical comparative effectiveness research (CER) studies. PCORI has identified the following areas as programmatic priorities:
- Methods to Improve the Use of Artificial Intelligence (AI) and Machine Learning (ML) in Clinical Research
- Methods to Improve Study Design
- Methods to Support Data Research Networks
- Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER
Letter of Intent: February 8, 2022. Application (by invitation): May 3, 2022.
InternationalCooley's Anemia Foundation 2022 Medical Research Grants & FellowshipsResearch Fellowship Grants: Up to USD $50,000 for 1 year. Research Fellowship Grants: For clinical and basic science postdoctoral or junior faculty investigators. Applications should be focused on the understanding or treatment of thalassemia or a complication that is related to thalassemia. Junior faculty applicants must have an M.D., Ph.D., or equivalent degree, and must have completed less than five years at the assistant professor level at the time the applications are due. Research Fellowship Grants: Deadline: February 7, 2022.
International
American Psychological Foundation (APF): Various Opportunities
APF Walter Katkovsky Research Grants for Early-Career Psychologists: Up to USD $20,000.
APF/Division 39 Grant: USD $7,000.
APF/The Trust Grant in Honor of Eric A. Harris, EdD, JD: USD $5,000.
David H. and Beverly A. Barlow Grant:Up to USD $7,500.
F.J. McGuigan Early Career Investigator Research Grant on Understanding the Human Mind: USD $11,500.
Marian R. Stuart Grant: Up to USD $20,000.
Visionary Grants: Up to USD $20,000.
Wayne F. Placek Grants: Up to $10,000.
APF Walter Katkovsky Research Grants for Mid and Senior-Level Psychologists: Up to USD $20,000.
NOTE: The above list includes those grants valued at least USD $5,000. Please see the APF website for other opportunites valued less than USD $5,000.
APF Walter Katkovsky Research Grants for Early-Career Psychologists:Support research on the general topic of psychotherapy. Applicant must be a psychologist with up to 12 years of postdoctoral experience.
APF/Division 39 Grant: Supports efforts in education, research, and service that advance and encourage the field of psychoanalysis.
APF/The Trust Grant in Honor of Eric A. Harris, EdD, JD:Supports an early career psychologist or graduate student for research or projects in the area of ethics and risk management. Applicant must be a graduate student or early career psychologist (no more than 10 years postdoctoral).
David H. and Beverly A. Barlow Grant: Supports innovative basic and clinical research on anxiety and anxiety-related disorders. Applicant must be a graduate student or early career researcher (no more than 10 years postdoctoral).
F.J. McGuigan Early Career Investigator Research Grant on Understanding the Human Mind:Supports research that aims to address any aspect of mental function (e.g., cognition, affect, motivation) and seeks to understand the mind from both a behavioral and neural perspective. Applicant must be no more than 10 years postdoctoral.
Marian R. Stuart Grant:Support to to further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Applicant must be an early career researcher (no more than 10 years postdoctoral).
Visionary Grants: Support research, education, and intervention projects and programs in the priority areas listed on the Visionary Grants webpage. Applicants must be a graduate student or early career researcher (no more than 10 years postdoctoral).
Wayne F. Placek Grants: Support empirical research from all fields of the behavioral and social sciences on any topic related to lesbian, gay, bisexual, or transgender issues. Graduate students and early career researchers are encouraged to apply.
APF Walter Katkovsky Research Grants for Mid and Senior-Level Psychologists: Support research on the general topic of psychotherapy.
APF Walter Katkovsky Research Grants for Early-Career Psychologists:February 15, 2022.
APF/Division 39 Grant: June 30, 2022.
APF/The Trust Grant in Honor of Eric A. Harris, EdD, JD: May 1, 2022
David H. and Beverly A. Barlow Grant:September 15, 2022.
F.J. McGuigan Early Career Investigator Research Grant on Understanding the Human Mind: March 1, 2022.
Marian R. Stuart Grant:July 1, 2022.
Visionary Grants: April 1, 2022.
Wayne F. Placek Grants: March 1, 2022.
APF Walter Katkovsky Research Grants for Mid and Senior-Level Psychologists: March 1, 2022.
InternationalEuropean Joint Foundation on Rare Diseases Transnational Call 2022: Development of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseasesFrom CIHR, up to $450,000 over 3 years.This call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project focused on a group of rare diseases or a single rare disease and based on complementarities and sharing of expertise, with expected impact to use the results in the future for benefit of patients. The topic is the development of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseases.Pre-Proposal: February 16, 2022.
Full Proposal (by invitation): June 15, 2022.
InternationalNew York Stem Cell Foundation (NYSCF) Neuroscience Investigator AwardsUp to USD $1.5M for 5 years.The goal of this initiative is to foster innovative, emerging scientists whose pioneering approaches have the potential to transform the field of neuroscience. Applicants are invited to apply from all fields in neuroscience. Applicants need not be working in areas related to stem cells or related areas. Applicants must be within 6 years of starting a faculty (professorship) or comparable position on June 1, 2022.February 16, 2022.
InternationalAnesthesia Patient Safety Foundation (APSF) Annual Investigator Initiated Research (IIR) GrantsUp to USD $150,000 total for up to 2 years.This program's objective is to stimulate and fund studies that will clearly improve patient safety and lead to prevention of mortality and morbidity resulting from anesthesia mishaps. Potential areas of research include a wide variety of safety patient topics.Letter of Intent: February 17, 2022.
Full Proposal (by invitation): Early August 2022.
InternationalAmerican Psychological Association (APA) Society for Clinical Neuropsychology (SCN) Early Career Pilot Study AwardsUp to USD $15,000 for one year.SCN is a scientific and professional organization of psychologists interested in the study of brain-behavior relationships, and the clinical application of that knowledge to human problems Eligible candidates are SCN members (including associates and student affiliates) who are within ten years of having completed their doctoral degree and are committed to basic or clinical research in the field of neuropsychology.February 25, 2022.
InternationalInternational Society for the Study of the Lumbar Spine (ISSLS) Research GrantUSD $20,000 per year.This is to promote research in the lumbar spine. The research proposal can be in basic science, biomechanics or the clinical field. The principal investigator must be less than 45 years of age. At least one investigator must be an ISSLS member.February 28, 2022.
InternationalInternational Lung Cancer Foundation (ICLF) Young Investigator GrantsUSD $50,000 for 1 yearThis funds the training of early-career researchers who wish to pursue careers in lung cancer diagnosis, treatment, or laboratory research as well as other aspects of the study of lung tumors. At the time of application, the applicant must: be within five years of initial faculty appointment; a member of the IASLC, and if selected for grant funding, must maintain IASLC membership for the duration of the grant.February 28, 2022.
InternationalPfizer Global Medical Grants (GMG) Request for Proposals (RFP): 2022 Global Hemophilia ASPIREBasic science project: Up to $90,000 per year for 1-2 years; Clinical science project: Up to $110,000 per year for 1-2 years.Projects that will be considered for Pfizer support will focus on the following areas:
- Basic and Clinical Science of Gene Therapy for Hemophilia
- Basic and Clinical Science of Tissue Factor Pathway Inhibitor (TFPI) and anti-TFPI monoclonal antibodies
- Burden of disease: Clinical Hemophilia A and B
March 1, 2022.
InternationalVascular Cures Wylie Scholar ProgramUSD $50,000 per year for up to 3 years.This provides a career development grant to outstanding young vascular surgeon-scientists who combine active patient care with academic research. The award may be used to support research in the following areas: basic science, translational, clinical research, outcomes/health services research, teaching, community service, and patient care. The candidate must be within 5 years of their first faculty appointment at the time of application. Only one nomination per institution per year will be considered, and please see opportunity for additional criteria that must be met. If you are interested in applying, please let us know by emailing VPRI@smh.ca. March 1, 2022.
InternationalGilead Sciences Research Scholars Program in Solid TumorsUSD $65,000 per year for 2 years.The program is designed to support innovative basic, translational and clinical scientific research related to Oncology Solid Tumors. This award is intended for junior faculty who are in the early stages of their career and are planning to become independent investigators. Applicants must hold an MD, PhD, or equivalent degree at time of award, be within 7 years of a faculty appointment, and be able to devote approximately 30-50% of professional time to research (versus administrative, patient care, or teaching responsibilities).March 1, 2022.
InternationalAlzheimer's Drug Discovery Foundation (ADDF): Diagnostics Accelerator (DxA) and Target ALS Foundation Biomarker Discovery Request for Proposals (RFP)Up to USD $100,000 per year for up to 3 years.This is to fund biomarker research targeting biomarkers that might be common to disease pathways or pathophysiologies in Alzheimer’s disease, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) to facilitate biomarker discovery and validation. In doing so, the Diagnostics Accelerator and Target ALS aim to drive towards an improved understanding of the heterogeneity of these neurodegenerative diseases and offer potential solutions for differential diagnosis.Letter of Intent: March 2, 2022.
Full Proposal (by invitation): May 6, 2022.
InternationalZOLL FoundationTypically in the USD $10,000-$50,000 range.This invites studies in the fields of resuscitation or acute critical care that aim to improve practices, prevent patient deterioration, reduce mortality and morbidity, or address some other aspect of enhancing care. Grant applicants should be newer researchers, ideally recommended by a more established investigator.March 31, 2022.
InternationalAmerican Academy of Child and Adolescent Psychiatry (AACAP): Various OpportunitiesEach grant has a value of USD $15,000.Applicants must be board eligible/certified in child and adolescent psychiatry or enrolled in a child psychiatry residency or fellowship program. At the time of application, candidates may not have more than two years of research experience following graduation from residency/fellowship training. Applicants must either be AACAP members or have a membership application pending.
- Pilot Research Award for Attention Disorders: For early career faculty for pilot research on psychiatric conditions that involve attentional dysfunction. Value: USD $15,000.
- Pilot Research Award for Learning Disabilities: For a child and adolescent psychiatry early career faculty member for pilot research on psychiatric conditions that involve learning dysfunction. Value: USD $15,000.
- Pilot Research Award for Early Career Faculty: For early career faculty who have an interest in beginning a career in child and adolescent psychiatry research. Value: USD $15,000.
April 1, 2022.
InternationalNIH Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required)--National Institute of Mental Health seeks applications for pilot research to develop and test just-in-time adaptive intervention augmentations to enhance the effectiveness and clinical potency of established adolescent mental health treatments. An emphasis is placed on studies that are informed by developmental science and grounded in an empirical model of behavior change.June 22, 2022; February 22, 2023.
InternationalPre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Amyotrophic Lateral Sclerosis Research Program (ALSRP)Pilot Clinical Trial Award:Up to USD $2,000,000 for up to 3 years; Clinical Care Tier: For applications not investigating a novel therapeutic, but proposing a clinical trial to optimize established ALS clinical care. Value: Up to USD $1,000,000 for up to 3 years.
Therapeutic Development Award: Up to USD $1,000,000 total costs for up to 3 years.
Clinical Biomarker Development Award: Up to USD $500,000 for up to 4 years. Faculty Award: Focuses on the PI’s research and career development. Value: Up to USD $500,000 for up to 2 years.
Therapeutic Idea Award:Up to USD $500,000 for up to 2 years. Biomarker Option: For applications that include development of biomarkers in parallel to the main therapeutic effort. Value: Up to USD $600,000 for up to 2 years.
This is anticipated to provide funding for the ALSRP to support the development of effective treatments for amyotrophic lateral sclerosis (ALS).
Pilot Clinical Trial Award: Supports exploratory clinical trials of novel therapeutics to demonstrate feasibility and inform the design of more advanced trials in ALS.
Therapeutic Development Award: Supports secondary preclinical validation and Investigational New Drug (IND)-enabling studies of therapeutics for ALS.
Clinical Biomarker Development Award: Supports maximization of clinical ALS resources and biorepositories to better define subtypes, predict therapeutic response, or assess prognosis.
Therapeutic Idea Award: Supports hypothesis-driven preclinical therapeutic development. Projects focusing primarily on investigating ALS pathophysiology, without consideration of therapeutic development, are outside the scope of this award mechanism.
Pre-application and application deadlines will be available when the announcements are released.
InternationalPre-Announcement: US Department of Defense (DOD) Office of the Congressionally Directed Medical Research Programs (CDMRP): FY22 Peer Reviewed Epilepsy Research Program (ERP)Idea Development Award: Funding Level 1: Up to USD $300,000 for up to 3 years; Funding Level 2: Up to USD $550,000 for up to 3 years.
Research Partnership Award: Up to USD $1.3M total costs for up to 3 years.
Virtual Post-Traumatic Epilepsy Research Center (P-TERC): Up to USD $1.25M for up to 4 years. Faculty Award: Focuses on the PI’s research and career development. Value: Up to USD $500,000 for up to 3 years.
This is anticipated to provide funding for the ERP to understand the mechanisms of post-traumatic epilepsy (PTE).
Idea Development Award: Supports novel, innovative research to understand the magnitude and underlying mechanisms of PTE. Value: Funding Level 1: Up to USD $300,000 for up to 3 years; Funding Level 2: Up to USD $550,000 for up to 3 years.
Research Partnership Award: To create an avenue for synergistic, collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. Value: Up to USD $1.3M total costs for up to 3 years.
Virtual Post-Traumatic Epilepsy Research Center (P-TERC): Leadership Award: Applicants will act as the Director and Deputy Director to lead the center in meeting its overarching goal. Value: Up to USD $1.25M for up to 4 years. Faculty Award: Focuses on the PI’s research and career development. Value: Up to USD $500,000 for up to 3 years.
Pre-application and application deadlines will be available when the announcements are released.
InternationalPfizer Global Medical Grants (GMG): COVID-19 Vaccine Grants--COVID-19 Vaccine General Research (now open): Pfizer is accepting COVID-19 general research grant requests that address the following areas: Studies evaluating COVID-19 burden of disease and sero-epidemiological surveys among specific populations.
- Epidemiology studies evaluating direct & indirect impact, including modeling approaches, of Pfizer's vaccine particularly in specific patient populations.
- Studies measuring the impact of efforts to overcome vaccine hesitancy and enhance vaccine uptake.

COVID-19 Vaccine Independent Medical Education (coming soon): Optimize the prevention of COVID-19 by:
- Increase awareness of the risk of COVID-19 for all ages and racial and ethnic groups.
- Increase the understanding, and familiarity with, the proper storage, handling and administration of Pfizer's vaccine.

Vaccine General Research: Rolling submission.

Independent Medical Education: TBA
InternationalAlzheimer's Association: International Research Grant Program --Multiple OpportunitiesVarious
InternationalSolving Kids Cancer (SKC): Therapeutic Development Initiative (TDI) - Funding for High-Impact Pediatric Cancer Research$50,000 to $500,000 USD for up to 2 years.The TDI of SKC only supports clinical research.Preliminary Proposal Deadline: Ongoing
InternationalÖssur Orthopaedic Research Grant Program--This provides funding for scientific inquiry in the areas of lower extremity biomechanics, dynamic/active rehabilitation, ortho biologics, functional bracing, clinical patient outcomes, and, related healthcare economics.Rolling Deadline
InternationalGateway for Cancer Research (GFCR): Various OpportunitiesGFCR Grant Program: USD $200,000 to $1.5 million for 2-5 years

GFCR Integrative Program:USD $200,000 to $1.5 million for 2-5 years.

SIO / Gateway Integrative Research Grant Program: Value: USD $200,000 to $1.5 million for 2-5 years.
Gateway funds Phase I and II patient-centered cancer clinical trials that have the potential to shift the paradigm for standard of care, focusing on the following priority research areas: Biomarkers/Molecular Markers (genomic or proteomic); Gene Therapy; Histology Agnostic/Basket Trial; Immunotherapy; Targeted Therapies. Focus is on the following therapeutic areas: New Investigational Therapies; Novel Use or Approach; Precision Medicine; Integrative Medicine.

GFCR Grant Program: Funds early phase clinical trials for cancers of all types at renowned institutions around the world.

GFCR Integrative Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

SIO / Gateway Integrative Research Grant Program: Funds integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

GFCR Decentralized (DCTI) Grant Program: Leverages site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients doorsteps.
GFCR Grant Program: Rolling Deadline

GFCR Integrative Program:Rolling Deadline

SIO / Gateway Integrative Research Grant Program: Rolling Deadline

InternationalAesculap Implant Systems Investigator-Initiated Study Program (IIS)--This supports researchers interested in conducting studies of their own design, which promotes the advancement of medical and scientific knowledge related to Aesculap's products and therapeutic areas of focus: Neurosurgery; Surgical Technologies; Closure Technologies; Orthopaedics; Spine; Biologics.Continuous intake
InternationalBausch + Lomb Grants--Educational Grants: These contribute to the improvement of patient care and advances in the use of healthcare products. Grand-rounds, lectures, symposiums and workshops are funded to educate medical students, university faculty, physicians, nurse practitioners, optometrists, ophthalmologists, allied health professionals, optical research scientists and associations of optometry and ophthalmology about improvements in ocular health.
Independent Research Grant: These empower the global research community to develop new treatments and technological advancements in ocular health. Research Grants have been funded by to improve consumers' standard of care, efficacy, patient satisfaction, safety and vision performance.
Rolling submission. Allow 6-12 weeks for proposal review and decision.
NIH NIH Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease and Related Dementias (AD/ADRD)--These support applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).
- PAR-21-207 (R01 Clinical Trial Optional): Specifically supports ancillary studies to ongoing, early- to late-stage clinical intervention trials. Ancillary studies should provide the opportunity to explore novel psychological and interpersonal mechanisms by collecting new data from participants enrolled in the ongoing parent study.
January 26, 2022.
NIHNIH Patient Activation for Self-Management of Chronic Conditions (R01 Clinical Trial Optional)--This encourages grant applications that address the influence of patient activation on self-management of chronic conditions.New Applications: February 5, 2022; June 5, 2022; February 5, 2023; AIDS Applications: September 7, 2021; May 7, 2022; September 7, 2022; May 7, 2023.
NIHNIH Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed)

--This encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness.February 5, 2022; June 5, 2022; October 5, 2022; February 5, 2023; June 5, 2023; October 5, 2023; February 5, 2024; June 5, 2024.
NIHNIH NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)--This is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies.February 9, 2022; June 9, 2022; October 11, 2022; February 9, 2023; June 9, 2023; October 10, 2023; February 9, 2024.
NIHNIH Dementia Care and Caregiver Support Intervention Research--R01 Research Project Grant - Clinical Trial Required: This solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care.

R61/R33 - Clinical Trial Required: This will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings. This will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
February 10, 2022; October 11, 2022; February 10, 2023; October 10, 2023; February 13, 2024.
NIHSingle-Site Investigator-Initiated Clinical Trials (R61/R33)--This grant supports applications to develop and implement investigator-initiated single site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.February 11, 2022; June 10, 2022
NIHData Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)
--This grant supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies.February 11, 2022; June 10, 2022
NIHNIH Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)--The National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial.February 11, 2022; June 10, 2022; October 11, 2022; February 10, 2023; June 13, 2023; October 11, 2023; February 13, 2024; June 11, 2024; October 11, 2024.
NIHNIH National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunity Announcements (FOAs): Various Opportunities--NIMH solicits clinical trial applications through a series of FOAs that cover the intervention development pipeline, from first-in-human, early testing of new interventions, confirmatory efficacy trials, through to effectiveness trials.

PAR-21-129: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
PAR-21-130: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
PAR-21-131: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
PAR-21-132: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
PAR-21-134: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
PAR-21-135: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
PAR-21-136: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-21-137: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
February 15, 2022; June 15, 2022; October 14, 2022; February 15, 2023; June 15, 2023; October 17, 2023; February 15, 2024.
NIHNIH HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)--This supports high priority research at the intersection of HIV and substance use. It is open to both individual researchers and research teams and includes all areas of research from basic science to clinical and implementation research.February 15, 2022; August 15, 2022; February 15, 2023; August 15, 2023; February 15, 2024.
NIHNIH Tobacco Regulatory Science (R01 Clinical Trial Optional)--This supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).February 15, 2022; July 14, 2022; February 14, 2023.
NIHNIH Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
--This encourages theoretically-driven pilot and/or feasibility research in the following areas: 1) the development and pilot testing of new or adapted interventions to prevent or delay the initiation of substance use and/or the progression from use to misuse or disorder and 2) services research examining questions specific to the prevention of substance use. The latter may include pilot studies of strategies or approaches to intervention, and/or other service system-based research to address areas such as economics, funding, service quality and engagement. Other outcomes of interest include a reduction in negative sequalae such as deaths related to impaired driving, suicidal behavior (e.g., nonfatal and fatal attempts), and substance-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings.February 16, 2022; June 16, 2022; October 16, 2022; February 16, 2023; June 16, 2023; October 16, 2023.
NIHNIH Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)--This supports collaborative studies of a unique resource of patient-derived iPSC lines generated by the National Eye Institute (NEI) AMD Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. The goal is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD.February 17, 2022.
NIHNIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional)--This encourages investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.February 18, 2022; June 20, 2022; October 18, 2022; February 21, 2023; June 19, 2023; October 18, 2023; February 20, 2024.
NIHNational Cancer Institute (NCI) Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)--This grant supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. February 22, 2022; June 21, 2022
NIHNIH Pilot Effectiveness Trials of Interventions for Preschoolers with ADHD (R34 Clinical Trial Required)Up to USD $450,000 for up to 3 years.This is pilot projects to evaluate the preliminary effectiveness of interventions targeting preschool attention deficit hyperactivity disorder (ADHD) symptoms and impairments. An emphasis is placed on studies that take a theory-driven, empirical approach to developing and testing interventions intended to impact current ADHD symptoms and impairments and/or prevent or forestall the emergence of co-occurring disorders or additional ADHD-related impairments.March 1, 2022.
NIHNIH HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)_The focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target.March 2, 2022; June 2, 2022; October 4, 2022; February 2, 2023; June 2, 2023; October 4, 2023; February 2, 2024; June 4, 2024; October 2, 2024.
NIHNIH Accelerating the Pace of Drug Abuse Research Using Existing Data_This invites applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. Primary data collection is not allowed for applications.
R21 Clinical Trial Optional
R01 Clinical Trial Optional
March 4, 2022; August 5, 2022; November 15, 2022; March 7, 2023; August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; November 15, 2024.
NIHNIH Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)



--This encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024.
NIHNIH Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)--The National Institute on Drug Abuse (NIDA) CEBRA fosters highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research.March 8, 2022; August 10, 2022; March 8, 2023; August 10, 2023; March 8, 2024.
NIHNIH Research on Current Topics in Alzheimer's Disease and Its Related DementiasThis invites applications proposing research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD). Further information on the high-priority topics of interest will be announced through a series of Notices published subsequent to this announcement. Applications proposing research on topics beyond those specified in the notices will not be prioritized for funding.
- - R21 Clinical Trial Optional: For applications that need additional preliminary data with broader dissemination to establish them for more general use in this research field.
- - R01 Clinical Trial Optional
March 11, 2022; July 8, 2022; November 14, 2022; March 10, 2023; July 10, 2023; November 13, 2023; March 11, 2024; July 9, 2024; November 12, 2024.
NIHNIH Social Disconnection and Suicide Risk in Late Life--This encourages research that addresses the link between social disconnection in late-life and late-life suicidal thoughts and behaviors. Of specific interest is research that identifies mechanisms by which social disconnection confers risk for, and social integration protects against, suicidal thoughts and behaviors in late life. Mechanisms to be considered exist at multiple levels of analysis, including but not limited to neurobiological, behavioral, and environmental
- - R21 Clinical Trial Optional: Most appropriate for high risk/high payoff projects that lack preliminary data.
- - R01 Clinical Trial Optional: For applications with preliminary data.
March 15, 2022; October 15, 2022.
NIHIntegrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)--The intent of this funding is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.March 17, 2022; July 19, 2022; November 7, 2022
NIHNIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)--This seeks to broaden and strengthen patient-centric translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH).PAR-21-342: Pre-application (recommended, not required). Deadlines: December 13, 2022; December 13, 2023.
PAR-21-343: Application. Deadlines: April 18, 2022; April 18, 2023; April 18, 2024.
NIHNIH Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research--This is for exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities.
R61 Clinical Trial Not Allowed: This is suitable for projects that are at their inception, conceptual, or idea-based phase. In this phase, the technical feasibility of the proposed technology or methodology should not yet have been established.
R33 Clinical Trial Not Allowed: This is suitable for projects that have overcome major feasibility gaps for the technology or methodology as demonstrated with supportive preliminary data but still require further development and rigorous validation to encourage adoption by the research community.
April 22, 2022; September 22, 2022.
NIHNIH Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)--The purpose is to support basic science research, from early exploratory studies to therapeutic discovery and development, in novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.Standard dates apply until May 8, 2022.
NIHNIH Dissemination and Implementation Research in Health--This supports innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

- PAR-19-274 (R01 Clinical Trial Optional)
- PAR-19-275 (R21 Clinical Trial Optional)
-PAR-19-276 (R03 Clinical Trial Not Allowed)
Standard dates apply until May 8, 2022.
NIHNIH Advancing communication strategies to support future HIV vaccine use--This invites applications that will advance novel health communication research designed to inform and support acceptance and uptake of future vaccines that protect against HIV. Research should focus on understanding key drivers for HIV vaccine communication success, communication strategies for engagement of communities placed at greatest risk for acquiring HIV, and/or mitigating the impact and reach of HIV vaccine misinformation. Research applications may leverage HIV vaccine analogs (e.g., COVID-19, HPV, HBV vaccines), so long as they have a primary focus on populations placed at risk for HIV, and/or healthcare settings and providers involved in HIV prevention delivery.
- R01 Clinical Trial Optional: Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials should consider using the R01 mechanism.
- R21 Clinical Trial Optional: Applicants proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models or applications should consider the R21 mechanism.
May 10, 2022.
NIHNeural Regulation of Cancer
- PAR-19-353 (R01 Clinical Trial Not Allowed)
- PAR-19-354 (R21 Clinical Trial Not Allowed)
--These opportunities encourage collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer.27-May-22
NIHNIH Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)

--This supports applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (e.g. epidemiologic, biomedical, behavioral, health care delivery or clinical).June 7, 2022; October 7, 2022; June 7, 2023; October 9, 2023; June 7, 2024; October 8, 2024
NIHNIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)--The goal of this funding opportunity announcement (FOA) is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic / pharmacodynamic (PK/PD) studies are also responsive. This FOA is not specific for any one or group of pain conditions.June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023.
NIHNIH HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)--The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards. The limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. June 9, 2022; October 11, 2022; June 9, 2023; and October 10, 2023.
NIHNIH Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery: Various Opportunities--This invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing.
- PAR-21-349 (R01 Basic Experimental Studies with Humans Required): Types of projects include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolation. Applications should not propose a goal of clinical outcomes or products.
- PAR-21-350 (R01 Clinical Trials Not Allowed): For applications that propose studies including model animal research or observational studies involving humans. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.
- PAR-21-352 (R01 Clinical Trial Required): Types of projects include mechanistic studies that are classified as clinical trials. Types of studies include clinical trials that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
June 21, 2022; June 21, 2023; June 21, 2024.
NIHNIH Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)--This supports exploratory studies developing or using novel tools or technologies or testing novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in CNS HIV establishment and expansion. This promotes research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.July 14, 2022; September 7, 2022.
NIHNew Models of Integrated HIV/AIDS, Addiction, and Primary Care Service
- PAR-20-273 (R01 Clinical Trial Required)
- PAR-20-274 (R34 - Clinical Trial Optional)
--This supports the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services.
- PAR-20-273 (R01 Clinical Trial Required): This seeks applications that will test comprehensive service delivery models. Applicants needing to develop, refine, and/or test key components of such a model are encouraged to apply to the companion R34.
- PAR-20-274 (R34 - Clinical Trial Optional): The R34 grant mechanism is intended to encourage planning research by providing support for the initial development of a clinical trial or research project.
August 11, 2022; November 18, 2022; August 11, 2023
NIHGrand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)
--The purpose of this grant is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval.Applications will be accepted on a rolling basis, expiring on September 1, 2022.
NIHNIH Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)--The primary objective is to move Digital Therapeutics (DTx) to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for Substance Use Disorders (SUDs). Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications.September 8, 2022; January 10, 2023; September 8, 2023; January 10, 2024.
NIHNotice of Special Interest (NOSI): Research in the Emergency Setting--This notice invites basic, translational and clinical research and career development programs that effect all areas of emergency medical care, including injury and trauma. Please see opportunity details for the lists of NIH Institutes and Centers and associated funding opportunity announcements to use for submission of an application in response to this NOSI.This notice applies to receipt dates through September 8, 2022.
NIHNIH Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children--This highlights interest in research to understand the mental health impact of the COVID-19 pandemic on school-aged children, specifically ages 3 - 12. Particularly, NIH is interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. This notice applies to subsequent receipt dates through September 8, 2022.
NIHNIH National Library of Medicine Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional)

--The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. The scope of NLM's interest in these research domains is broad, with emphasis on new methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, reusable approaches to discovery, curation, analysis, organization and management of health-related digital objects.Standard dates apply until September 8, 2022.
NIHNIH Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)--This supports studies that accelerate our understanding of the roles of complement components and/or receptors in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents, or of the roles played by complement in the development of immune-mediated pathogenic responses following infection. The results of such studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.This notice applies to subsequent receipt dates through January 7, 2023.
NIHCo-infection and Cancer
- PAR-20-062 (R01 Clinical Trial Not Allowed)
- PAR-20-061 (R21 Clinical Trial Not Allowed)
--The purpose is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents - either concurrently or sequentially- and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.Standard dates apply until January 8, 2023.
NIHFundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)--This encourages projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. This is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.Standard dates apply until January 8, 2023.
NIHNIH Notice of Special Interest (NOSI): Promoting Pain Research Within the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Mission Areas--This NOSI invites research applications that focus on improving the understanding of mechanisms of acute and chronic pain, and enhancing knowledge that will help better prevent, manage and reduce pain and improve health equity of all populations suffering from acute or chronic pain caused by rheumatic, autoinflammatory, musculoskeletal, and skin diseases and conditions within the NIAMS mission.This notice applies to due dates on or after November 5, 2021 and subsequent receipt dates through January 10, 2023.
NIHNIH Notice of Special Interest (NOSI): Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration--The specific research objectives of this NOSI are to rapidly expand the knowledge base on acute and long-term neurological and neurocognitive sequelae of COVID-19. NIA encourages investigator-initiated new and resubmission applications for research activity codes (i.e., R21, R01, R03) to address significant questions about the neurological and neurocognitive impacts of COVID-19 infection in aging and the interaction in older adults of COVID-19 with comorbid conditions, including Alzheimer's disease (AD) and AD-related dementias (ADRD). This notice applies to subsequent receipt dates through May 7, 2023.
NIHNIH Notice of Special Interest (NOSI): Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised)--This seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries.This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through May 8, 2023.
NIHNotice of Special Interest (NOSI): Adopting Techniques and Tools Developed from the BRAIN Initiative Toward National Institute of Mental Health (NIMH) Strategic Research Priorities--NIMH is encouraging the submission of applications proposing to use the following types of tools/technologies developed in the BRAIN Initiative:
- Technologies that enable causal in vivo behavioral neuroscience experimental designs to probe functions of neural circuits implicated in the above-mentioned behavioral domains
- Technologies that analyze and manipulate complex circuits with a goal to provide comprehensive circuit diagrams
- Technologies that monitor neural activity and in vivo behaviors
- Interventional tools
- Technologies that allow examination of developmental time course and/or sex differences in mental health-relevant circuit function
- Computational modeling approaches and data analysis
This notice applies to receipt dates through May 8, 2023.
NIHNotice of Special Interest (NOSI): Research on Rehabilitation Needs Associated with the COVID-19 Pandemic--The purpose of this NOSI is to encourage applications in three areas related to the intersection of COVID-19, the associated mitigation actions, and rehabilitation:
- Encourage research to address the rehabilitation needs of survivors of COVID-19
- Understand the impact of disruptions to rehabilitation services caused by the COVID-19 pandemic and associated mitigation actions
- Understand the social, behavioral, economic, and health impact of the COVID-19 pandemic and the associated mitigation actions on people with physical disabilities
This notice applies to receipt dates through May 8, 2023.
NIHNIH Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)--This supports research that improves our understanding of the behavioral, social, and economic effects of the pandemic and to enhance our ability to control its spread. These effects will likely be particularly acute for NIH-designated health disparity populations , and other COVID-19 vulnerable groups including older adults, who have experienced higher rates of COVID-19 infection, who in some cases rely on the efforts of paid and unpaid care partners, and who may have additional barriers to accessing the medical system itself. Further, middle-aged and older frontline healthcare and essential workers and their families face unique risks of exposure to both infection and other health-related outcomes by virtue of their employment.This notice applies to receipt dates May 8, 2023.
NIHOccupational Safety and Health Research (R01)
--The purpose is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries.Standard dates apply until November 18, 2023.
NIHNIH Notice of Special Interest (NOSI): Understanding the effects of cancer and cancer treatment on aging trajectories and aging outcomes--This supports applications that aim to better understand the effects of a cancer diagnosis and subsequent cancer treatment on aging trajectories and aging outcomes. These include, but are not limited to:
- Investigation of aging trajectories associated with specific cancer treatments and identification of cancer survivors at risk for an "accelerated aging" phenotype;
- Examination of the effects of specific cancer treatments on aging biology that may alter aging trajectories or aging outcomes;
- Development and/or validation of tools, technologies, measures, or techniques for the identification of late-emerging effects and aging phenotypes among cancer survivors;
- Use of old and young animal models to determine the effects of established and newer cancer therapies on aging endpoints;
- Development and/or testing of interventions designed to prevent, mitigate or reverse the adverse aging-related effects of cancer and cancer treatments; and
- Development and/or testing of interventions focused on models and processes of care delivery to intervene at the intersection of cancer treatment and aging.
This notice applies to receipt dates through January 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers--This supports the secondary use of real-world data for Artificial Intelligence (AI)-based predictive modeling with the ultimate goal of improving early detection and risk assessment for abdominal cancers. This encourages applications proposing multi-institutional collaborative AI development approaches such as federated learning, which distributes the models to data-owners and aggregates the results without sharing the actual data.This notice applies to subsequent receipt dates through January 8, 2024.
NIHNIH Priority HIV/AIDS Research within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01 Clinical Trial Optional)
--This seeks to stimulate HIV/AIDS research within the mission of the NIDDK that align with the HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Standard AIDS dates apply until January 8, 2024.
NIHNIH Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R21 Clinical Trial Not Allowed)
--This is for innovative basic and translational pilot research projects within the mission of the NIDDK that are aligned with NIH HIV/AIDS research priorities. These priorities were most recently described in NOT-OD-20-018 UPDATE: NIH HIV/AIDS Research Priorities and Guidelines for Determining HIV/AIDS Funding. Potential topics could address multiple overarching priorities. Standard AIDS dates apply until January 8, 2024.
NIHCancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)--This supports investigator-initiated clinical that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.Standard dates apply until January 8, 2024.
NIHNotice of Special Interest (NOSI): Use of Predictive Analytics to Accelerate Late-Stage Implementation Research to Address Heart, Lung, Blood, and Sleep Disorders--National Heart, Lung, and Blood Institute (NHLBI) seeks to leverage existing data resources using Predictive Analytics Implementation Research (PAIR) that utilizes complex and innovative methodologies and modeling techniques to rely on integration of existing data to inform the designs (and often test) implementation strategies for heart, lung, blood, and sleep (HLBS) conditions. NHLBI also encourages applications which focus on the development of advance modeling techniques and data reporting, which would be publicly available and could be used to inform subsequent implementation strategies to address HLBS conditions.This notice applies to receipt dates through January 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition-This encourages applications in high-priority research areas related to pediatric health care transition for youth with chronic physical/medical conditions or intellectual/developmental disabilities. Research applications that will advance our understanding of promising practices designed to facilitate successful health care transitions (HCT) from pediatric to adult care settings as well as barriers and facilitators to such transition are encouraged.This notice applies to subsequent receipt dates through January 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Telehealth in Cancer Care--This supports investigator-initiated applications for conducting research on the use of telehealth in cancer-related care. Studies focused on populations that experience inequities in access to care and have worse cancer outcomes compared to the general population are strongly encouraged.This notice applies to subsequent receipt dates through March 8, 2024.
NIHNIH Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes--National Institute of Mental Health (NIMH) seeks applications to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus and intensity/burden.

PAR-21-211 (R34 Clinical Trial Required): This supports pilot research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials.

PAR-21-210 (R01 Clinical Trial Required): This supports fully-powered, definitive effectiveness studies focused on post-acute phase interventions
Standard dates apply until March 17, 2024.
NIHNIH Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies--National Institute of Allergy and Infectious Diseases (NIAID) is interested in the development and optimization of next generation methodologies for HIV-1 drug resistance (DR) mutation detection and reporting. Strategies applicable to low and middle income countries as defined by the World Bank are especially encouraged.

National Institute on Drug Abuse (NIDA) is interested in the following areas: Feasibility of self-administered, cost effective, and potential for mail-in testing and follow up through mobile technologies targeting substance-using populations living with HIV; Development of technologies that allow sensitive and rapid read out of drug resistance; Plans for post-administering surveys to assess rates of access, acceptability (stigma and ethical concerns), accuracy, and treatment outcomes; Technologies that are easily adaptable for implementation in homeless shelters, community clinics, criminal justice, and emergency department settings.
This notice applies to due dates on or after September 5, 2021 and subsequent receipt dates through May 7, 2024.
NIHNIH Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)--This supports exploratory and innovative research projects, which fall within the missions of the NINDS and NIMH. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community.Standard dates apply until May 8, 2024.
NIHNIH NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)--This supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. Standard dates apply until May 8, 2024.
NIHNotice of Special Interest (NOSI) regarding the Use of Human Connectome Data for Secondary Analysis--This encourages secondary analyses of data from the Human Connectome Project (HCP), including the multiple datasets in the Lifespan Human Connectome projects and the Human Connectomes Related to Human Disease. Applicants beyond the groups that originally collected the data are encouraged to apply. The analyses will serve to generate and evaluate hypotheses about the complex interrelationships among: brain structure, function and connectivity; cognitive, affective, sensory and motor processes; environmental factors; life event, social and psychosocial factors; genomic data, and clinical symptoms during development, aging, or disease.This notice applies to receipt dates through May 8, 2024.
NIHNIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD): Various OpportunitiesUp to USD $50,000 per year for up to 2 years. PA-21-231 (R03 Basic Experimental Studies with Humans Required): This is for basic science experimental studies involving humans. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research.

PA-21-221 (R03 Clinical Trial Required): This supports clinical trials that fall within the NICHD mission.
Standard dates apply until May 8, 2024.
NIHNIH Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment--The purpose is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. Each partnership should include at least one academic and one industrial organization.

PAR-21-166: R01 - Clinical Trial Not Allowed
PAR-21-206: R01 - Clinical Trial Optional

Standard dates apply until May 8, 2024.
NIHNIH Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity: Various Opportunities--The purpose of these Funding Opportunity Announcements (FOAs) is to lay the groundwork for developing interventions at the network/circuit level that might be used as potential treatments for cognitive, affective, or social deficits in psychiatric disorders. These FOAs support projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing.

PAR-21-175 (R01 Clinical Trial Optional)
PAR-21-176 (R21 Clinical Trial Optional)
Standard dates apply until May 8, 2024.
NIHNIH Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide--This is to communicate special interest in epidemiology investigations to quantify the impact of the COVID-19 pandemic on HIV prevention, incidence, transmission, and outcomes. This NOSI encourages research on the impact and strategies needed to adapt the HIV/AIDS response through agile and innovative support of prevention and care and the maintenance of sustained HIV viral suppression during the COVID-19 pandemic.This notice applies to due dates on or after September 7, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Promoting Vaccine Access, Acceptance and Uptake among Children, Adolescents, Pregnant and Lactating Women, and Persons with Disabilities--This NOSI encourages applications that address dimensions of access, acceptance and uptake of CDC-recommended vaccines among infants, children, adolescents, pregnant and lactating women, and persons with disabilities, especially among populations who are underserved or experience health disparities.This notice applies to due dates on or after September 8, 2021 and subsequent receipt dates through May 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health--This calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.This notice applies to subsequent receipt dates through June 8, 2024.
NIHNotice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)--This NOSI seeks to support investigation into the factors and molecular mechanisms that address the heterogeneity dictated by the host resilience. Research on general host responses to injurious challenges and their effects on lung function as well as mechanisms that impact susceptibility to ARDS is not considered to be responsive to this announcement.This notice applies to receipt dates through July 5, 2024.
NIHNIH Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning--This encourages grant applications proposing research that makes use of available, large data sets with the objective of improving HIV epidemic modeling and service planning, with greater attention to the role of substance use. National Institute on Drug Abuse (NIDA) is interested in applications that make use of existing data, such as epidemiologic cohorts, clinic cohorts and longitudinal follow-up studies of interventions, as well as other publicly available sources of data including data warehouses and commercial data sources. Substance use should be a key component of any research supported by this NOSI.This notice applies to subsequent receipt dates through September 7, 2024.
NIHNIH Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19--National Institute on Drug Abuse (NIDA) is interested in receiving research applications focusing on individuals with HIV who smoke or vape marijuana, tobacco, cocaine and/or methamphetamine to determine the long-term effects of their use among individuals with HIV and COVID-19. This notice applies to due dates through September 7, 2024.
NIHNotice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection--This NOSI encourages research to understand:
- The risks that smoking or vaping tobacco or marijuana may have on acquiring the COVID-19 infection.
- The medical consequences, co-morbidity, and complications of COVID-19 infection in individuals who smoke or vape tobacco or marijuana.
- The medical consequences of COVID-19 in individuals who smoke and vape with comorbid conditions such as: SUD, HIV and other immunosuppressive diseases, mental health disorders, diabetes mellitus, obesity, cardiovascular, pulmonary, renal, and hepatic pathologies, as well as cancer.
This notice applies to due dates through September 8, 2024.
NIHNIH Basic Research in Cancer Health Disparities--This encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities.

- R01 Clinical Trial Not Allowed: These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities.

- R21 Clinical Trial Not Allowed: This provides support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities.

- R03 Clinical Trial Not Allowed These small research grants will support projects on cancer health disparities that can be carried out in a short period of time with limited resources.
Standard dates apply until September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): Behavioral Economics for Implementation Research (BEIR) to improve use of Evidence-Based Practices for heart, lung, blood, and sleep (HLBS) conditions



--National Heart, Lung, and Blood Institute (NHLBI) encourages applications that recognize the importance of cultural context, patterns of behavior change, and motivators for change across decision-making levels, including individuals (e.g., patients, parents, clinicians, others), groups, healthcare systems and/or communities.This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.
NIHNIH Notice of Special Interest (NOSI): International Research Collaboration on Drug Abuse and Addiction Research



--The purpose of this notice is to encourage collaborative research applications that take advantage of opportunities outside of the US. Applications examining all areas of National Institute on Drug Abuse (NIDA)-supported research addressing the causes, consequences, treatment, and prevention of drug use, misuse, and addiction are encouraged. Projects should be conducted through newly formed or well-established partnerships between an investigator in a US-based institution and a scientist working in another country.This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through September 8, 2024.
NIHNIH Clinical Trial Readiness for Functional Neurological Disorders (FNDs) (U01 Clinical Trial Optional) --This invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this funding opportunity announcement include the validation of biomarkers, endpoints and clinical outcome assessments that are fit-for-purpose and have a defined context of use for clinical trialsStandard dates apply until November 6, 2024.
NIHNIH Neuromodulation/Neurostimulation Device Development for Mental Health Applications--This encourages applications seeking to develop the next generation of brain stimulation devices for treating mental health disorders. Applications are encouraged that will either 1) develop novel brain stimulation devices or 2) significantly enhance, by means of hardware/software improvements, the effectiveness of brain stimulation devices that are currently FDA-approved or cleared.
- R01 Clinical Trial Not Allowed: For applicants who seek to propose a larger project. Applicants who seek to establish proof-of-concept should respond to the companion R21.
-R21 Clinical Trial Not Allowed: This uses the R21 grant mechanism, encouraging shorter, higher-risk applications. Applications that seek to study scientific or clinical hypotheses that simply utilize devices are outside the scope.
Standard dates apply until January 8, 2025.
NIHNIH NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed) --This provides support for activities central to the refinement and completion of a study protocol and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that restore vision in humans through regeneration of cells. Applicants may use this grant to support the development of a detailed Manual of Procedures, to collect safety/toxicity data, to conduct preliminary studies evaluating feasibility, or collecting other pre-clinical data of regenerative strategies as part of the planning process.Standard dates apply until January 8, 2025
NIHNIH Drug Discovery for Nervous System Disorders --NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.
R01 Clinical Trials Not Allowed: Applicants with preliminary data may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21 mechanism.
R21 Clinical Trials Not Allowed: This will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).
Standard dates apply until January 8, 2025
NIHNIH Notice of Special Interest (NOSI): Promoting Cardiovascular and Cardiometabolic Health in Early Stages of the Lifecourse: Pre-adolescence Through Adolescence to Young Adulthood --This supports support research to: 1) understand the mechanisms and the pathogenesis of cardiometabolic health and cardiovascular disease (CVD) risk in vulnerable groups throughout transitionary phases, from pre-adolescence (6-10 years) through adolescence (11-18 years) to young adulthood (19-39 years), and 2) develop precision prevention interventions (at the individual and populations levels) to address cardiovascular and cardiometabolic risk across these transitionary phases.This notice applies to due dates on or after October 5, 2021 and subsequent receipt dates through June 5, 2026.
NIHNIH Parent Announcements --NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) (PA-20-184)

Research Project Grant (Parent R01 Clinical Trial Required) (PA-20-183)

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) (PA-20-200)

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) (PA-20-195)

NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) (PA-20-194)

NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) (PA-20-196)
Standard dates apply unless otherwise stated.
X